10-Q: Arbutus Biopharma Reports First Quarter 2024 Financial Results and Provides Business Update

Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, while advancing its hepatitis B virus (HBV) therapeutic pipeline and ongoing patent litigation.

Summary

• Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, compared to a net loss of $16.3 million for the same period in 2023.
• Total revenue for the quarter was $1.5 million, a decrease from $6.7 million in the first quarter of 2023, primarily due to lower collaboration and license revenue.
• Research and development expenses decreased to $15.4 million from $18.3 million year-over-year, due to the discontinuation of certain programs.
• The company's cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2024.
• Arbutus believes it has sufficient cash to fund operations for at least the next 12 months and through the second quarter of 2026.
• The company expects a net cash burn between $63 million and $67 million in 2024, excluding proceeds from its Open Market Sale Agreement.
• Arbutus is advancing its HBV pipeline, including imdusiran (AB-729) in Phase 2a trials and AB-101 in a Phase 1a/1b trial.
• The company is also involved in ongoing patent litigation against Moderna and Pfizer/BioNTech regarding their use of Arbutus's LNP technology in COVID-19 vaccines.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is advancing its pipeline, the increased net loss and decreased revenue are concerning. The ongoing patent litigation adds uncertainty. Overall, the sentiment is neutral to slightly negative.

Positives

• Arbutus has a strong cash position of $137.9 million, which is expected to fund operations through the second quarter of 2026.
• The company is actively advancing its HBV pipeline with multiple Phase 2a trials for imdusiran and a Phase 1a/1b trial for AB-101.
• The claim construction ruling in the Moderna patent litigation was largely in favor of Arbutus.
• The company has a clear strategy focused on developing a functional cure for chronic hepatitis B infection.
• Arbutus has a collaboration with Qilu Pharmaceuticals for the development and commercialization of imdusiran in China.

Negatives

• The company experienced a net loss of $17.9 million in Q1 2024, an increase from the $16.3 million loss in Q1 2023.
• Total revenue decreased significantly to $1.5 million in Q1 2024 from $6.7 million in Q1 2023.
• Research and development expenses, while decreased, still represent a significant portion of the company's operating expenses.
• The company is involved in ongoing patent litigation, which can be costly and time-consuming.

Risks

• The company's success is dependent on obtaining regulatory approvals for its products.
• The outcome of ongoing patent litigation is uncertain and could impact the company's financial position.
• The company's research and development programs are subject to risks and uncertainties, including clinical trial delays and failures.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• The company's revenue is dependent on collaborations and licenses, which can fluctuate.

Future Outlook

Arbutus believes it has sufficient cash resources to fund its operations through the second quarter of 2026 and expects a net cash burn between $63 million and $67 million in 2024, excluding proceeds from its Open Market Sale Agreement. The company plans to continue advancing its HBV pipeline and pursuing its patent litigation.

Management Comments

• The company believes the key to success in developing a functional cure involves suppressing hepatitis B virus deoxyribonucleic acid, reducing hepatitis B surface antigen and boosting HBV-specific immune responses.
• The company continues to protect and defend its intellectual property, which is the subject of the company's on-going lawsuits against Moderna and Pfizer/BioNTech for their use of its patented LNP technology in their COVID-19 vaccines.

Industry Context

Arbutus is operating in the competitive biopharmaceutical industry, focusing on developing a functional cure for chronic hepatitis B. The company's approach involves combining multiple therapeutic modalities, including RNAi therapeutics and immune modulators, which aligns with current trends in the field. The ongoing patent litigation highlights the importance of intellectual property in this sector.

Comparison to Industry Standards

• Arbutus's cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway is longer than many of its peers.
• The company's focus on a combination therapy approach for HBV is consistent with the industry's move towards more effective and durable treatments.
• The ongoing patent litigation is a significant factor that could impact the company's future revenue streams, similar to other companies in the sector that rely on intellectual property.
• The company's clinical trial progress is comparable to other companies in the HBV space, with multiple Phase 2a trials underway.
• Companies like Gilead Sciences and Vir Biotechnology are also working on HBV cures, making the competitive landscape intense.

Legal Proceedings

• Arbutus and Genevant are involved in patent infringement litigation against Moderna and Pfizer/BioNTech.
• Arbutus and Genevant are involved in a declaratory judgment lawsuit with Acuitas.
• Arbutus is involved in an Inter Partes Review petition filed by Moderna regarding one of its patents.
• Arbutus is involved in European patent opposition proceedings with Moderna and Merck.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the outcome of ongoing litigation.
• Employees are impacted by the company's financial stability and the progress of its research and development programs.
• Patients with chronic hepatitis B are impacted by the company's efforts to develop a functional cure.
• Collaborators and licensees are impacted by the company's progress in developing and commercializing its products.

Next Steps

• The company will continue to advance its Phase 2a clinical trials for imdusiran.
• The company will continue to evaluate AB-101 in its Phase 1a/1b clinical trial.
• The company expects to report end-of-treatment data from the AB-729-201 clinical trial at the EASL Congress in June 2024.
• The company expects to report end-of-treatment data from the AB-729-202 clinical trial at the EASL Congress in June 2024.
• The company expects to report preliminary end-of-treatment data from the additional cohort of the AB-729-202 clinical trial in the second half of 2024.
• The company expects to report preliminary data from Part 2 of the AB-101-001 clinical trial in the second half of 2024.
• The company will continue to pursue its patent litigation against Moderna and Pfizer/BioNTech.
• The company will continue to screen patients for the AB-729-203 clinical trial.

Key Dates

Keywords

Hepatitis B, HBV, Imdusiran, AB-729, AB-101, RNAi, PD-L1 inhibitor, Clinical trials, LNP technology, Patent litigation, Financial results, Biopharmaceutical